Eli Lilly reported higher profit and raised its outlook on surging demand for its weight-loss drugs, sending its shares ...

Eli Lilly chairman and CEO David Ricks joins CNBC’s “Squawk on the Street” team to discuss its quarterly earnings report that ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled to $3.57 billion in the third quarter. Meanwhile, revenue ...

A woman has taken to the internet to share the biggest difference she experienced when switching between GLP-1 drugs Wegovy ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U. Food and Drug Administration's new ...

Meghan Trainor showed off her flat abs in a mirror selfie with coach Bella Maher after the pop star went through a weight ...

Worth noting, CVS Caremark—the biggest PBM in the U.S.— announced in May that it would make Novo Nordisk’s rival drug Wegovy ...

Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.

The company sees no supply constraints for tirzepatide, a concern that has plagued other players in the GLP-1 space globally.

Eli Lilly raised its full-year profit and revenue forecasts on Thursday as strong international demand for weight-loss drugs ...

Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive shift from the Danish ...